Dr. Jennifer M. Specht
Claim this profileSeattle Cancer Care Alliance / University of Washington
Area of expertise
Breast Cancer
Jennifer M. Specht has run 11 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Jennifer M. Specht has run 5 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
Seattle Cancer Care Alliance / University Of Washington
Fred Hutchinson Cancer Center
Clinical Trials Jennifer M. Specht is currently running
CAR T-Cell Preparation
for Cancer
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Recruiting
1 award
N/A
3 criteria
PET Imaging
for Breast Cancer
This clinical trial studies how well fluorine F 18 fluorthanatrace (\[18F\]FTT) positron emission tomography (PET) works in imaging patients with breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) who are receiving standard of care (SOC) poly (ADP-ribose) polymerase (PARP) inhibitors with or without immune checkpoint inhibitors (ICI) to be able to detect clinical response to PARP inhibitor ± ICI treatment. \[18F\]FTT is a radiotracer that targets and binds to PARP1 which can potentially be used for the imaging of PARP1 expression using PET. Once administered, \[18F\]FTT targets and binds to PARP1. Upon PET, PARP1-expressing tumor cells can be visualized. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case, \[18F\]FTT. Because some cancers take up \[18F\]FTT it can be seen with PET. PARP inhibitors work as a targeted therapy by blocking an enzyme involved in repairing cell damage. It may cause tumor cells to die. ICI may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Combining \[18F\]FTT with a PET scan may help detect tumor cells better in patients with metastatic breast cancer who are receiving standard of care PARP inhibitors with our without ICI treatment.
Recruiting
1 award
Phase 1 & 2
4 criteria
More about Jennifer M. Specht
Clinical Trial Related
4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Jennifer M. Specht has experience with
- Fludeoxyglucose F-18
- Pembrolizumab
- Ladiratuzumab Vedotin
- Trastuzumab
- Niraparib
- Computed Tomography
Breakdown of trials Jennifer M. Specht has run
Breast Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer M. Specht specialize in?
Jennifer M. Specht focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Jennifer M. Specht currently recruiting for clinical trials?
Yes, Jennifer M. Specht is currently recruiting for 3 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Jennifer M. Specht has studied deeply?
Yes, Jennifer M. Specht has studied treatments such as Fludeoxyglucose F-18, Pembrolizumab, ladiratuzumab vedotin.
What is the best way to schedule an appointment with Jennifer M. Specht?
Apply for one of the trials that Jennifer M. Specht is conducting.
What is the office address of Jennifer M. Specht?
The office of Jennifer M. Specht is located at: Seattle Cancer Care Alliance / University of Washington, Seattle, Washington 98109 United States. This is the address for their practice at the Seattle Cancer Care Alliance / University of Washington.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.